While our study provides evidence that the secretion of complement proteins and activation of the ISR pathway drives OC progression and platinum resistance, further elucidation of the specific signaling pathways downstream of ATF4 and the ISR, as well as the precise mechanisms by which complement factors influence cancer cell behavior, will be critical for the development of novel therapeutic strategies. This evidence concerns the gene ATF4 and cancer.